Skip to main content

Advertisement

SpringerLink
Log in

Prognostic Impact of Renin–Angiotensin System Blockade on Renal Cell Carcinoma After Surgery

  • Urologic Oncology
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Background

Angiotensin 2 is a key biologic peptide in the renin–angiotensin system (RAS) that regulates blood pressure and renal hemodynamics. The potential role of the RAS in the promotion of tumor growth, angiogenesis, and metastasis also has been shown in the past few decades. This study investigated the prognostic impact of RAS blockade on patients with renal cell carcinoma (RCC) after surgery.

Methods

The study identified 557 patients with pathologically diagnosed RCC (pT1-4 N0M0) and evaluated the prognostic factors after surgery for patients administered or not administered angiotensin-converting enzyme inhibitors (ACEs) or angiotensin 2 receptor blockers (ARBs).

Results

The median follow-up period was 5.1 years. Radical nephrectomy was performed for 349 patients (62.7 %), whereas the remaining 208 patients (37.3 %) underwent partial nephrectomy. A total of 104 patients (18.7 %) were administered RAS inhibitors: ACEs (n = 22) or ARBs (n = 82). Multivariate analysis showed that administration of RAS inhibitors (P = 0.044; HR 2.69), longer tumor length (P < 0.001; HR 1.02), high-grade tumor (P < 0.001; HR 3.55), and positive microvascular invasion (P < 0.003; HR 3.13) were not independent risk factors for a decrease in subsequent disease-specific survival after surgery for RCC. The 5-year disease-specific survival rate was 96.8 % among the patients administered RAS inhibitors and 89.8 % among their counterparts (P = 0.019).

Conclusions

The authors propose renin–angiotensin blockade as a possible potent choice for effective treatment after surgical treatment of RCC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma. N Engl J Med. 1996;335:865–75.

    Article  CAS  PubMed  Google Scholar 

  2. Guinan PD, Vogelzang NJ, Fremgen AM, et al. Renal cell carcinoma: tumor size, stage, and survival. Members of the Cancer Incidence and End Results Committee. J Urol. 1995;153(3 Pt 2):901–3.

  3. Figlin RA. Renal cell carcinoma: management of advanced disease. J Urol. 1999;161:381–6; (discussion 386–7).

  4. Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet. 2007;370:2103–11.

    Article  PubMed  Google Scholar 

  5. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356:125–34.

    Article  CAS  PubMed  Google Scholar 

  6. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356:115–24.

    Article  CAS  PubMed  Google Scholar 

  7. Lever AF, Hole DJ, Gillis CR, et al. Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer? Lancet. 1998;352:179–84.

    Article  CAS  PubMed  Google Scholar 

  8. Egami K, Murohara T, Shimada T, et al. Role of host angiotensin II type 1 receptor in tumor angiogenesis and growth. J Clin Invest. 2003;112:67–75.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  9. Juillerat-Jeanneret L, Celerier J, Chapuis Bernasconi C, et al. Renin and angiotensinogen expression and functions in growth and apoptosis of human glioblastoma. Br J Cancer. 2004;90:1059–68.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  10. Ager EI, Neo J, Christophi C. The renin-angiotensin system and malignancy. Carcinogenesis. 2008;29:1675–84.

    Article  CAS  PubMed  Google Scholar 

  11. George AJ, Thomas WG, Hannan RD. The renin-angiotensin system and cancer: old dog, new tricks. Nat Rev Cancer. 2010;10:745–59.

    Article  CAS  PubMed  Google Scholar 

  12. Miyajima A, Kosaka T, Asano T, Seta K, Kawai T, Hayakawa M. Angiotensin II type I antagonist prevents pulmonary metastasis of murine renal cancer by inhibiting tumor angiogenesis. Cancer Res. 2002;62:4176–9.

    CAS  PubMed  Google Scholar 

  13. Kosugi M, Miyajima A, Kikuchi E, Horiguchi Y, Murai M. Angiotensin II type 1 receptor antagonist candesartan as an angiogenic inhibitor in a xenograft model of bladder cancer. Clin Cancer Res. 2006;12:2888–93.

    Article  CAS  PubMed  Google Scholar 

  14. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130:461–70.

    Article  CAS  PubMed  Google Scholar 

  15. Grandi AM, Maresca AM. Blockade of the renin-angiotensin-aldosterone system: effects on hypertensive target organ damage. Cardiovasc Hematol Agents Med Chem. 2006;4:219–28.

    Article  CAS  PubMed  Google Scholar 

  16. Arrieta O, Guevara P, Escobar E, Garcia-Navarrete R, Pineda B, Sotelo J. Blockage of angiotensin II type I receptor decreases the synthesis of growth factors and induces apoptosis in C6 cultured cells and C6 rat glioma. Br J Cancer. 2005;92:1247–52.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  17. Greco S, Muscella A, Elia MG, et al. Angiotensin II activates extracellular signal regulated kinases via protein kinase C and epidermal growth factor receptor in breast cancer cells. J Cell Physiol. 2003;196:370–7.

    Article  CAS  PubMed  Google Scholar 

  18. Khakoo AY, Sidman RL, Pasqualini R, Arap W. Does the renin-angiotensin system participate in regulation of human vasculogenesis and angiogenesis? Cancer Res. 2008;68:9112–5.

    Article  CAS  PubMed  Google Scholar 

  19. Ronquist G, Rodriguez LA, Ruigomez A, et al. Association between captopril, other antihypertensive drugs, and risk of prostate cancer. Prostate. 2004;58:50–6.

    Article  CAS  PubMed  Google Scholar 

  20. Christian JB, Lapane KL, Hume AL, Eaton CB, Weinstock MA, Trial V. Association of ACE inhibitors and angiotensin receptor blockers with keratinocyte cancer prevention in the randomized VATTC trial. J Natl Cancer Inst. 2008;100:1223–32.

    Article  CAS  PubMed  Google Scholar 

  21. Uemura H, Ishiguro H, Nakaigawa N, et al. Angiotensin II receptor blocker shows antiproliferative activity in prostate cancer cells: a possibility of tyrosine kinase inhibitor of growth factor. Mol Cancer Ther. 2003;2:1139–47.

    CAS  PubMed  Google Scholar 

  22. Tatokoro M, Fujii Y, Kawakami S, et al. Phase II trial of combination treatment of interferon-alpha, cimetidine, cyclooxygenase-2 inhibitor, and renin-angiotensin-system inhibitor (I-CCA therapy) for advanced renal cell carcinoma. Cancer Sci. 2011;102:137–43.

    Article  CAS  PubMed  Google Scholar 

  23. Wilop S, von Hobe S, Crysandt M, Esser A, Osieka R, Jost E. Impact of angiotensin I converting enzyme inhibitors and angiotensin II type 1 receptor blockers on survival in patients with advanced non–small cell lung cancer undergoing first-line platinum-based chemotherapy. J Cancer Res Clin Oncol. 2009;135:1429–35.

    Article  CAS  PubMed  Google Scholar 

  24. Keizman D, Huang P, Eisenberger MA, et al. Angiotensin system inhibitors and outcome of sunitinib treatment in patients with metastatic renal cell carcinoma: a retrospective examination. Eur J Cancer. 2011;47:1955–61.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  25. Sipahi I, Debanne SM, Rowland DY, Simon DI, Fang JC. Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials. Lancet Oncol. 2010;11:627–36.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  26. Collaboration ARBT. Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138,769 individuals. J Hypertens. 2011;29:623–35.

    Google Scholar 

  27. Shirotake S, Miyajima A, Kosaka T, et al. Regulation of monocyte chemoattractant protein-1 through angiotensin II type 1 receptor in prostate cancer. Am J Pathol. 2012;180:1008–16.

    Article  CAS  PubMed  Google Scholar 

  28. Shirotake S, Miyajima A, Kosaka T, et al. Angiotensin II type 1 receptor expression and microvessel density in human bladder cancer. Urology. 2011;77:1009, e1019–25.

    Google Scholar 

  29. Yuge K, Miyajima A, Tanaka N, et al. Prognostic value of renin-angiotensin system blockade in non-muscle-invasive bladder cancer. Ann Surg Oncol. 2012;19:3987–93.

    Article  PubMed  Google Scholar 

  30. Tanaka N, Miyajima A, Kikuchi E, et al. Prognonstic impact of renin-angiotensin system blockade in localised upper-tract urothelial carcinoma. Br J Cancer. 2012;106:290–6.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

Download references

Conflict of interest

There are no conflicts of interest.

Author information

Author notes

    Authors and Affiliations

    1. Department of Urology, Keio University School of Medicine, Tokyo, Japan

      Akira Miyajima MD, Satoshi Yazawa MD, Takeo Kosaka MD, Nobuyuki Tanaka MD, Suguru Shirotake MD, Ryuichi Mizuno MD, Eiji Kikuchi MD & Mototsugu Oya MD

    Authors
    1. Akira Miyajima MD
      View author publications

      You can also search for this author in PubMed Google Scholar

    2. Satoshi Yazawa MD
      View author publications

      You can also search for this author in PubMed Google Scholar

    3. Takeo Kosaka MD
      View author publications

      You can also search for this author in PubMed Google Scholar

    4. Nobuyuki Tanaka MD
      View author publications

      You can also search for this author in PubMed Google Scholar

    5. Suguru Shirotake MD
      View author publications

      You can also search for this author in PubMed Google Scholar

    6. Ryuichi Mizuno MD
      View author publications

      You can also search for this author in PubMed Google Scholar

    7. Eiji Kikuchi MD
      View author publications

      You can also search for this author in PubMed Google Scholar

    8. Mototsugu Oya MD
      View author publications

      You can also search for this author in PubMed Google Scholar

    Corresponding author

    Correspondence to Akira Miyajima MD.

    Additional information

    Satoshi Yazawa have contributed equally to this work.

    Rights and permissions

    Reprints and permissions

    About this article

    Check for updates. Verify currency and authenticity via CrossMark

    Cite this article

    Miyajima, A., Yazawa, S., Kosaka, T. et al. Prognostic Impact of Renin–Angiotensin System Blockade on Renal Cell Carcinoma After Surgery. Ann Surg Oncol 22, 3751–3759 (2015). https://doi.org/10.1245/s10434-015-4436-0

    Download citation

    • Received:

    • Published:

    • Issue Date:

    • DOI: https://doi.org/10.1245/s10434-015-4436-0

    Keywords

    Search

    Navigation